SpringerProtocols: Abstract: ELISA Method for Measurement of Amyloid-ß Levels

ELISA Method for Measurement of Amyloid-ß Levels

By: Stephen D. Schmidt², Ralph A. Nixon^{2 3}, Paul M. Mathews^{2 4}

Abstract

Full Text

Download PDF (4913K)

The neuritic plaque in the brain of Alzheimer's disease (AD) patients consists of an amyloid composed primarily of Aß, an approx 4-kDa peptide derived from the amyloid precursor protein. Multiple lines of evidence suggest that Aß plays a key role in the pathogenesis of the disease, and potential treatments that target Aß production and/or Aß accumulation in the brain as ß-amyloid are being aggressively pursued. Methods to quantitate the Aß peptide are, therefore, invaluable to most studies aimed at a better understanding of the molecular etiology of the disease and in assessing potential therapeutics. Although other techniques have been used to measure Aß in the brains of AD patients and ß-amyloid-depositing transgenic mice, the enzyme-linked immunosorbent assay (ELISA) is one of the most commonly used, reliable, and sensitive methods for quantitating the Aß peptide. Here we describe methods for the recovery of both soluble and deposited Aß from brain tissue and the subsequent quantitation of the peptide by sandwich ELISA.

Affiliation(s): (2) Center for Dementia Research, Nathan Kline Institute, Orangeburg, NY
(3) Departments of Psychiatry and Cell Biology, New York University School of Medicine, New York, NY
(4) Department of Psychiatry, New York University School of Medicine, New York, NY

Book Title: Amyloid Proteins: Methods and Protocols

Series: Methods in Molecular Biology | Volume: 299 | Pub. Date: Dec-28-2004 | Page Range: 279-297 | DOI: 10.1385/1-59259-874-9:279

Subject: Protein Science

Key Words: Aß - amyloid - enzyme-linked immunosorbent assay (ELISA) - extraction - quan-tification - quantitation - Alzheimer's disease - amyloid precursor protein (APP) - formic acid - brain

References

Download References

1.	Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., and Beyreuther, K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 82,4245–4249.

2.	De Strooper, B. and Annaert, W. (2000) Proteolytic processing and cell biologi-cal functions of the amyloid precursor protein. J. Cell Sci. 113, 1857–1870.

3.	Goate, A., Chartier-Harlin, M. C., Mullan, M., et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704–706.

4.	Chartier-Harlin, M. C., Crawford, F., Houlden, H., et al. (1991) Early-onset Alzheimer%s disease caused by mutations at codon 717 of the ß-amyloid precursor protein gene. Nature 353, 844–846.

5.	Levy, E., Carman, M. D., Fernandez-Madrid, I. J., et al. (1990) Mutation of the Alzheimer%s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248, 1124–1126.

6.	Tanzi, R. E. and Bertram, L. (2001) New frontiers in Alzheimer's disease genetics. Neuron 32, 181–184.

7.	Mullan, M., Houlden, H., Windelspecht, M., et al. (1992) A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 14, proximal to the a1-antichymotrypsin gene. Nat. Genet. 2, 340–342.

8.	Levy-Lahad, E., Wasco, W., Poorkaj, P., et al. (1995) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973–977.

9.	Rogaev, E. I., Sherrington, R., Rogaeva, E. A., et al. (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376, 775–778.

10.	Sherrington, R., Rogaev, E. I., Liang, Y., et al. (1995) Cloning of a gene bear-ing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754–760.

11.	Cai, X. D., Golde, T. E., and Younkin, S. G. (1993) Release of excess amyloid ß protein from a mutant amyloid beta protein precursor. Science 259, 514–516.

12.	Citron, M., Oltersdorf, T., Haass, C., et al. (1992) Mutation of the ß-amyloid precursor protein in familial Alzheimer's disease increases ß-protein production. Nature 360, 672–674.

13.	Borchelt, D. R., Thinakaran, G., Eckman, C. B., et al. (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate Aß1-42/1-40 ratio in vitro and in vivo. Neuron 17, 1005–1013.

14.	Citron, M., Westaway, D., Xia, W., et al. (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid ß-protein in both transfected cells and transgenic mice. Nat. Med. 3, 67–72.

15.	Lemere, C. A., Lopera, F., Kosik, K. S., et al. (1996) The E280A presenilin 1 Alzheimer mutation produces increased Aß42 deposition and severe cerebellar pathology. Nat. Med. 2, 1146–1150.

16.	Hsiao, K., Chapman, P., Nilsen, S., et al. (1996) Correlative memory deficits, Aß elevation, and amyloid plaques in transgenic mice. Science 274, 99–102.

17.	Games, D., Adams, D., Alessandrini, R., et al. (1995) Alzheimer-type neuro-pathology in transgenic mice overexpressing V717F ß-amyloid precursor protein. Nature 373, 523–527.

18.	Sturchler-Pierrat, C., Abramowski, D., Duke, M., et al. (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA 94, 13287–13292.

19.	Duff, K., Eckman, C., Zehr, C., et al. (1996) Increased amyloid-ß42(43) in brains of mice expressing mutant presenilin 1. Nature 383, 710–713.

20.	Holcomb, L., Gordon, M. N., McGowan, E., et al. (1998) Accelerated Alzheimertype phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4, 97–100.

21.	Janus, C., Pearson, J., McLaurin, J., et al. (2000) Aß peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979–982.

22.	Meyer-Luehmann, M., Stalder, M., Herzig, M. C., et al. (2003) Extracellular amyloid formation and associated pathology in neural grafts. Nat. Neurosci. 6, 370–377.

23.	Rozmahel, R., Huang, J., Chen, F., et al. (2002) Normal brain development in PS1 hypomorphic mice with markedly reduced β-secretase cleavage of ßAPP. Neurobiol. Aging 23, 187–194.

24.	Rozmahel, R., Mount, H. T., Chen, F., et al. (2002) Alleles at the Nicastrin locus modify presenilin 1-deficiency phenotype. Proc. Natl. Acad. Sci. USA 99, 14452–14457.

25.	Pfeifer, M., Boncristiano, S., Bondolfi, L., et al. (2002) Cerebral hemorrhage after passive anti-Aß immunotherapy. Science 298, 1379.

26.	Mathews, P. M., Jiang, Y., Schmidt, S. D., Grbovic, O. M., Mercken, M., and Nixon, R. A. (2002) Calpain activity regulates the cell surface distribution of amyloid precursor protein: inhibition of calpains enhances endosomal generation of ß-cleaved C-terminal APP fragments. J. Biol. Chem. 277, 36415–36424.

27.	Grbovic, O. M., Mathews, P. M., Jiang, Y., et al. (2003) Rab5-stimulated upregulation of the endocytic pathway increases intracellular ß-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Aß production. J. Biol. Chem. 278,31261–31268.

28.	Gravina, S. A., Ho, L., Eckman, C. B., et al. (1995) Amyloid ß protein (Aß) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at Aß40 or Aß42(43). J. Biol. Chem. 270, 7013–7016.

29.	Savage, M. J., Trusko, S. P., Howland, D. S., et al. (1998) Turnover of amyloid ß-protein in mouse brain and acute reduction of its level by phorbol ester. J. Neurosci. 18, 1743–1752.

30.	Phinney, A. L., Drisaldi, B., Schmidt, S. D., et al. (2003) In vivo reduction of amyloid-ß by a mutant copper transporter. Proc. Natl. Acad. Sci. USA 100,14193–14198.

31.	Chishti, M. A., Yang, D. S., Janus, C., et al. (2001) Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276, 21562–21570.

Comments (Loading...)

Post comment/View all comments